

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

STA Relugolix for treating hormone-sensitive prostate cancer [ID6187]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was raised during scope consultation that black men are not represented in the trial as patient subgroups. Subgroups are only presented geographically (North and South America, Europe and Asia Pacific) rather than by ethnicity. Baseline risk for black men with cardiovascular risk factors and diagnosis of advanced prostate cancer may lead to different outcomes.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The draft remit and scope do not discriminate against people with a protected characteristic. Committee will decide the extent to which a NICE recommendation in this therapy area could have an impact on people protected by the equality legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): Emily Crowe

Date: 30/10/2023